Pharma Mar (BME:PHM) Stock Faces Clinical Setback Despite Royalty Strength

Pharma Mar stock closed at €80.15 after the market absorbed its half year 2026 update, leaving investors weighing a flat near term share price against a very different earnings picture. The company delivered resilient recurring oncology revenues and stayed cash generative, yet quarterly profit slipped into a small loss of €0.972m even as trailing twelve month earnings from continuing operations reached €56.126m.

The real story now sits on the longer horizon. Royalty growth, the Zepzelca rollout and a solid €126.4m net cash position frame how investors will judge Pharma Mar over the next few years, rather than this quarter’s dip in profit.

Love Pharma Mar’s cash generative oncology base but concerned about that quarterly loss line? Take a look at our list of solid balance sheet and fundamentals stocks (419 results).

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: €49.605m vs. €56.392m (declined 12.0%)
• Net Income/Loss, Q2 2026 vs. Q2 2025: loss of €0.972m vs. profit of €23.37m (swung to loss)
• Basic EPS, Q1 2026 vs. Q2 2025: €0.0883 (Q1 2026) vs. €1.3406 (Q2 2025) (fell 93.4%)
• Net Profit Margin, trailing 12 months vs. prior year: 25.7% vs. 22.2% (improved by 3.5 percentage points)

Prefer clean visuals instead of another wall of quarterly figures and margin percentages? See Pharma Mar’s full financial picture with an at a glance view of its valuation and cash position in the company report for Pharma Mar.

Pharma Mar Bull Case Hangs On Zepzelca Milestones

The bullish story on Pharma Mar is that growing Zepzelca use and rising royalties can reshape earnings while R&D reinvestment seeds the next wave of oncology assets. The latest half year numbers give that view some backing. Recurring revenues look solid with Zepzelca net sales up 23% and total royalty income up 46%. Management also reports that early launch in Germany and Austria is tracking ahead of expectations, which supports the idea that first line maintenance approvals can broaden adoption.

At the same time, the failed LAGOON Phase III trial in relapsed small cell lung cancer in June is a clear miss against the idea of an unchallenged growth engine. The stock’s flat 7 day move and mixed 90 day return around €80.15 suggest investors are still weighing strong recurring cash flow and a €126.4m net cash position against that clinical setback.

Compare Pharma Mar’s royalty momentum and Zepzelca rollout with what the street is actually pricing in. See the consensus price target analysis for Pharma Mar

Pharma Mar Bear Fears On Concentration Risk Partly Land

The bearish view is that Pharma Mar is over reliant on Zepzelca and too exposed if key clinical or commercial milestones slip. The failed LAGOON Phase III trial in relapsed small cell lung cancer is a clear miss. It directly supports fears that not every pivotal study will turn into a durable revenue pillar.

However, the latest half year numbers do not show the earnings air pocket that bears might expect from that setback. Recurring oncology revenues held up, with Zepzelca net sales and royalties growing enough to largely offset the absence of 2025 one off items. Operating cash flow of €11.9m and a higher net cash balance of €126.4m also run against the idea of immediate financial strain.

The core concentration risk remains, but this print points more to clinical disappointment than to a broken cash engine today.

After a key trial failure, highly volatile trading and reliance on one oncology pillar, review our independent risk analysis for Pharma Mar which shows 1 important warning sign

Stay Ahead With Simply Wall St

If Pharma Mar’s mix of resilient oncology revenues, a recent quarterly loss and a strong net cash position has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for a better entry point. Once you are invested, use the Portfolio Command Center to cut through market noise and focus on the key developments that matter to your holdings. For a broader view, tap into crowd insights and different angles on Pharma Mar and other stocks through the Community. By spotting potential catalysts and risks early, you give yourself a better chance to react quickly and stay ahead of the market.

Seeking Alternatives Beyond Pharma Mar?

Fresh ideas can move quickly. Some stocks are building breakout momentum while others stay under the radar for now. Check these focused lists before the best entry points are caught. Act now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com